Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Xenamed Corp. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner working within 1 distinct art unit. The presence of 1 distinct examiner for 1 pending office action indicates that the company's active legal engagement is limited to this technical review process. This arrangement of the assigned examiner and the assigned art unit defines the company's current prosecution efforts at the patent office.
The busiest examiner for this portfolio is TRAN, SUSAN T, who is responsible for 1 pending office action. This represents the entirety of the company's active workload at the USPTO. Practitioners can expect an interaction based on the requirements of TRAN, SUSAN T and the 1 distinct art unit involved. Because there is 1 pending office action for the busiest examiner, the company's strategy is dependent on the individual review of the assigned examiner within the Biotechnology & Pharmaceuticals sector. This focus determines the coordination required for the company's current patent filings.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, SUSAN T | 1 | 63.0% | +34.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18999388 | EXTENDED RELEASE MIDODRINE HYDROCHLORIDE COMPOSITIONS AND METHODS OF USE | TRAN, SUSAN T | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18999388 | EXTENDED RELEASE MIDODRINE HYDROCHLORIDE COMPOSITIONS AND METHODS OF USE | TRAN, SUSAN T | 1615 | §102Other | Non-Final OA | — | Pending | Dec 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialXenamed Corp. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Susan T Tran has the most, with 1 of Xenamed Corp.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
